|
|
Gene Symbol |
PF4 |
|
Aliases |
CXCL4, PF-4, SCYB4 |
|
Entrez Gene ID |
|
|
Gene Name |
Platelet factor 4 |
|
Chromosomal Location |
4q13.3 |
|
HGNC ID |
|
|
Summary |
This gene encodes a member of the CXC chemokine family. This chemokine is released from the alpha granules of activated platelets in the form of a homotetramer which has high affinity for heparin and is involved in platelet aggregation. This protein is chemotactic for numerous other cell type and also functions as an inhibitor of hematopoiesis, angiogenesis and T-cell function. The protein also exhibits antimicrobial activity against Plasmodium falciparum. [provided by RefSeq, Oct 2014]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Platelet factor 4, C-X-C motif chemokine 4, chemokine (C-X-C motif) ligand 4, iroplact, oncostatin-A |
|
Function |
Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form. |
|
|
|
|
|
UniProt |
|
|
PDB |
|
|
|
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
Autoimmune Diseases |
|
Respiratory Tract Diseases |
Pneumonia |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
CXCL8 |
PCOS, Abnormal folliculogenesis |
|
2003 Rotterdam criteria |
Related
|
13 patients with PCOS, 11 normo-ovulatory patients as control |
Our study provides the first evidence of the pathophysiologic contribution of the well-known angiostatic protein, PF4, on human reproductive biology. The increase of the intrafollicular PF4 and its anti-permeability effect might affect the formation of FF and folliculogenesis in PCOS. |
|
|
|
|